(Pyr³)-Amyloid β-Protein (3-40)

Pyr-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH

Placeholder

Product Number: 4050043

CAS Number: 161818-04-8

€ 216.10 – € 380.90

Custom/Bulk Quote

Pack size available	0.5mg, 1mg

Please select pack size:

Pack size available

Clear

Add to your inquiry

Product Description

The pyroglutamate-modified amyloid-β peptides derived from Aβ40 and Aβ42 have gained considerable attention as potential key participants in the pathology of Alzheimer’s disease (AD) due to their abundance in AD brain, high aggregation propensity, stability, and cellular toxicity. Aβ40 and 42 can be N-terminally truncated by action of cathepsin B. The cyclization of Glu³ is catalyzed by glutaminyl cyclase. Hence, inhibition of these enzymes could be a therapeutic approach to AD.

ADS

ADS lookup

MSDS

MSDS lookup

Amyloid Beta Peptides & Alzheimer's Disease

Modification of the terminal residue of apelin-13 antagonizes its hypotensive action.

D.K.Lee et al., Endocrinology, 146, 231 (2005)

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation.

D.Schlenzig et al., J. Neurochem., 121, 774 (2012)

Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival.

C.Russo et al., J. Neurochem., 82, 1480 (2002)

Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease.

S.Jawhar et al., J. Biol. Chem., 286, 38825 (2011)

Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

G.Hook et al., J. Alzheimers Dis., 41, 129 (2014)

Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival.

C.Russo et al., J. Neurochem., 82, 1480 (2002)

Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease.

S.Jawhar et al., J. Biol. Chem., 286, 38825 (2011)

Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

G.Hook et al., J. Alzheimers Dis., 41, 129 (2014)

Salt form: Trifluoroacetate

Molecular weight: 4125.68

Chemical Formula: C₁₈₇H₂₈₃N₅₁O₅₃S

Storage Temperature: < -15°C

One Letter code: pEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV

Source: Synthetic

Old Product Number: H-7422

Country

Inquiry List